About Cartography Biosciences
Cartography Biosciences is an oncology company building a differentiated pipeline of antibody-based therapies — including T-cell engaging bispecific and multi-specific antibodies — that target novel and highly specific tumor antigens more precisely than existing therapeutics. Its proprietary ATLAS and SUMMIT drug discovery platforms leverage single-cell genomics, proteomics, and computational biology across hundreds of thousands of cell states and large-scale patient tumor profiling to identify tumor-selective antigens. The company's customers are ultimately cancer patients and oncology researchers, with a lead clinical program (CBI-1214) targeting colorectal cancer.
Company details
Funding
Total raised
$124M
Last stage
Growth
Investors
Founders
Kevin Parker
Kevin Parker is the CEO and co-founder of Cartography Biosciences. He completed his PhD at Stanford working at the interface of genomics, immunology, and computational biology.
LinkedIn
Ansuman Satpathy
MD, PhD; Associate Professor of Pathology and Immunology at Stanford University; Director of the Stanford Center for Immunotherapy Design; co-founder of Immunai, Santa Ana Bio, and Prox Biosciences; Venture Partner at Wing Venture Capital.
LinkedInHoward Chang
Dermatologist and Stanford University professor; Kevin Parker's PhD advisor whose lab's work in single-cell genomics and epigenomics formed a scientific foundation for Cartography Biosciences.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.